{
  "id": "56e6ec49edfc094c1f000005",
  "type": "factoid",
  "question": "Which is the target of the drug Denosumab?",
  "ideal_answer": "Denosumab (Dmab) is a fully human monoclonal antibody against the receptor activator of nuclear factor-\u03baB ligand (RANKL).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26504466",
    "http://www.ncbi.nlm.nih.gov/pubmed/26029270",
    "http://www.ncbi.nlm.nih.gov/pubmed/26508890",
    "http://www.ncbi.nlm.nih.gov/pubmed/26203221"
  ],
  "snippets": [
    {
      "text": "Denosumab is a human monoclonal antibody which specifically blocks receptor activator of nuclear factor \u03baB ligand and is a very potent antiresorptive drug. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26029270",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "denosumab, a monoclonal antibody against RANKL",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26203221",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Denosumab is a human monoclonal antibody indicated for the treatment of osteoporosis in postmenopausal women with a high risk of fractures. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26504466",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Denosumab (Dmab) is a fully human monoclonal antibody against the receptor activator of nuclear factor-\u03baB ligand (RANKL), which, through the prevention of the RANKL/RANK interaction, inhibits osteoclast-mediated bone resorption and significantly reduces the risk of vertebral, nonvertebral, and hip fractures. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26508890",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "receptor activator of nuclear factor-\u03baB ligand, RANKL"
}